Small-spot intensity-modulated proton therapy and volumetric-modulated arc therapies for patients with locally advanced non-small-cell lung cancer: A dosimetric comparative study

Chenbin Liu, Terence T. Sio, Wei Deng, Jie Shan, Thomas B. Daniels, William G. Rule, Pedro R. Lara, Shawn M. Korte, Jiajian Shen, Xiaoning Ding, Steven E. Schild, Martin Bues, Wei Liu

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Purpose: To compare dosimetric performance of volumetric-modulated arc therapy (VMAT) and small-spot intensity-modulated proton therapy for stage III non-small-cell lung cancer (NSCLC). Methods and Materials: A total of 24 NSCLC patients were retrospectively reviewed; 12 patients received intensity-modulated proton therapy (IMPT) and the remaining 12 received VMAT. Both plans were generated by delivering prescription doses to clinical target volumes (CTV) on averaged 4D-CTs. The dose-volume-histograms (DVH) band method was used to quantify plan robustness. Software was developed to evaluate interplay effects with randomized starting phases of each field per fraction. DVH indices were compared using Wilcoxon rank sum test. Results: Compared with VMAT, IMPT delivered significantly lower cord Dmax, heart Dmean, and lung V5 Gy[ RBE ] with comparable CTV dose homogeneity, and protection of other OARs. In terms of plan robustness, the IMPT plans were statistically better than VMAT plans in heart Dmean, but were statistically worse in CTV dose coverage, cord Dmax, lung Dmean, and V5 Gy[ RBE ]. Other DVH indices were comparable. The IMPT plans still met the standard clinical requirements with interplay effects considered. Conclusions: Small-spot IMPT improves cord, heart, and lung sparing compared to VMAT and achieves clinically acceptable plan robustness at least for the patients included in this study with motion amplitude less than 11 mm. Our study supports the usage of IMPT to treat some lung cancer patients.

Original languageEnglish (US)
JournalJournal of Applied Clinical Medical Physics
DOIs
StateAccepted/In press - Jan 1 2018

Fingerprint

Proton Therapy
Intensity-Modulated Radiotherapy
Non-Small Cell Lung Carcinoma
lungs
therapy
Protons
arcs
cancer
Cells
protons
dosage
Nonparametric Statistics
Lung
histograms
Prescriptions
Lung Neoplasms
Software
homogeneity

Keywords

  • intensity-modulated proton therapy
  • interplay effects
  • lung cancer
  • volumetric-modulated arc therapy

ASJC Scopus subject areas

  • Radiation
  • Instrumentation
  • Radiology Nuclear Medicine and imaging

Cite this

Small-spot intensity-modulated proton therapy and volumetric-modulated arc therapies for patients with locally advanced non-small-cell lung cancer : A dosimetric comparative study. / Liu, Chenbin; Sio, Terence T.; Deng, Wei; Shan, Jie; Daniels, Thomas B.; Rule, William G.; Lara, Pedro R.; Korte, Shawn M.; Shen, Jiajian; Ding, Xiaoning; Schild, Steven E.; Bues, Martin; Liu, Wei.

In: Journal of Applied Clinical Medical Physics, 01.01.2018.

Research output: Contribution to journalArticle

Liu, Chenbin ; Sio, Terence T. ; Deng, Wei ; Shan, Jie ; Daniels, Thomas B. ; Rule, William G. ; Lara, Pedro R. ; Korte, Shawn M. ; Shen, Jiajian ; Ding, Xiaoning ; Schild, Steven E. ; Bues, Martin ; Liu, Wei. / Small-spot intensity-modulated proton therapy and volumetric-modulated arc therapies for patients with locally advanced non-small-cell lung cancer : A dosimetric comparative study. In: Journal of Applied Clinical Medical Physics. 2018.
@article{76a54d93f1d04827a5ce2aff593a0d2e,
title = "Small-spot intensity-modulated proton therapy and volumetric-modulated arc therapies for patients with locally advanced non-small-cell lung cancer: A dosimetric comparative study",
abstract = "Purpose: To compare dosimetric performance of volumetric-modulated arc therapy (VMAT) and small-spot intensity-modulated proton therapy for stage III non-small-cell lung cancer (NSCLC). Methods and Materials: A total of 24 NSCLC patients were retrospectively reviewed; 12 patients received intensity-modulated proton therapy (IMPT) and the remaining 12 received VMAT. Both plans were generated by delivering prescription doses to clinical target volumes (CTV) on averaged 4D-CTs. The dose-volume-histograms (DVH) band method was used to quantify plan robustness. Software was developed to evaluate interplay effects with randomized starting phases of each field per fraction. DVH indices were compared using Wilcoxon rank sum test. Results: Compared with VMAT, IMPT delivered significantly lower cord Dmax, heart Dmean, and lung V5 Gy[ RBE ] with comparable CTV dose homogeneity, and protection of other OARs. In terms of plan robustness, the IMPT plans were statistically better than VMAT plans in heart Dmean, but were statistically worse in CTV dose coverage, cord Dmax, lung Dmean, and V5 Gy[ RBE ]. Other DVH indices were comparable. The IMPT plans still met the standard clinical requirements with interplay effects considered. Conclusions: Small-spot IMPT improves cord, heart, and lung sparing compared to VMAT and achieves clinically acceptable plan robustness at least for the patients included in this study with motion amplitude less than 11 mm. Our study supports the usage of IMPT to treat some lung cancer patients.",
keywords = "intensity-modulated proton therapy, interplay effects, lung cancer, volumetric-modulated arc therapy",
author = "Chenbin Liu and Sio, {Terence T.} and Wei Deng and Jie Shan and Daniels, {Thomas B.} and Rule, {William G.} and Lara, {Pedro R.} and Korte, {Shawn M.} and Jiajian Shen and Xiaoning Ding and Schild, {Steven E.} and Martin Bues and Wei Liu",
year = "2018",
month = "1",
day = "1",
doi = "10.1002/acm2.12459",
language = "English (US)",
journal = "Journal of Applied Clinical Medical Physics",
issn = "1526-9914",
publisher = "American Institute of Physics Publising LLC",

}

TY - JOUR

T1 - Small-spot intensity-modulated proton therapy and volumetric-modulated arc therapies for patients with locally advanced non-small-cell lung cancer

T2 - A dosimetric comparative study

AU - Liu, Chenbin

AU - Sio, Terence T.

AU - Deng, Wei

AU - Shan, Jie

AU - Daniels, Thomas B.

AU - Rule, William G.

AU - Lara, Pedro R.

AU - Korte, Shawn M.

AU - Shen, Jiajian

AU - Ding, Xiaoning

AU - Schild, Steven E.

AU - Bues, Martin

AU - Liu, Wei

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Purpose: To compare dosimetric performance of volumetric-modulated arc therapy (VMAT) and small-spot intensity-modulated proton therapy for stage III non-small-cell lung cancer (NSCLC). Methods and Materials: A total of 24 NSCLC patients were retrospectively reviewed; 12 patients received intensity-modulated proton therapy (IMPT) and the remaining 12 received VMAT. Both plans were generated by delivering prescription doses to clinical target volumes (CTV) on averaged 4D-CTs. The dose-volume-histograms (DVH) band method was used to quantify plan robustness. Software was developed to evaluate interplay effects with randomized starting phases of each field per fraction. DVH indices were compared using Wilcoxon rank sum test. Results: Compared with VMAT, IMPT delivered significantly lower cord Dmax, heart Dmean, and lung V5 Gy[ RBE ] with comparable CTV dose homogeneity, and protection of other OARs. In terms of plan robustness, the IMPT plans were statistically better than VMAT plans in heart Dmean, but were statistically worse in CTV dose coverage, cord Dmax, lung Dmean, and V5 Gy[ RBE ]. Other DVH indices were comparable. The IMPT plans still met the standard clinical requirements with interplay effects considered. Conclusions: Small-spot IMPT improves cord, heart, and lung sparing compared to VMAT and achieves clinically acceptable plan robustness at least for the patients included in this study with motion amplitude less than 11 mm. Our study supports the usage of IMPT to treat some lung cancer patients.

AB - Purpose: To compare dosimetric performance of volumetric-modulated arc therapy (VMAT) and small-spot intensity-modulated proton therapy for stage III non-small-cell lung cancer (NSCLC). Methods and Materials: A total of 24 NSCLC patients were retrospectively reviewed; 12 patients received intensity-modulated proton therapy (IMPT) and the remaining 12 received VMAT. Both plans were generated by delivering prescription doses to clinical target volumes (CTV) on averaged 4D-CTs. The dose-volume-histograms (DVH) band method was used to quantify plan robustness. Software was developed to evaluate interplay effects with randomized starting phases of each field per fraction. DVH indices were compared using Wilcoxon rank sum test. Results: Compared with VMAT, IMPT delivered significantly lower cord Dmax, heart Dmean, and lung V5 Gy[ RBE ] with comparable CTV dose homogeneity, and protection of other OARs. In terms of plan robustness, the IMPT plans were statistically better than VMAT plans in heart Dmean, but were statistically worse in CTV dose coverage, cord Dmax, lung Dmean, and V5 Gy[ RBE ]. Other DVH indices were comparable. The IMPT plans still met the standard clinical requirements with interplay effects considered. Conclusions: Small-spot IMPT improves cord, heart, and lung sparing compared to VMAT and achieves clinically acceptable plan robustness at least for the patients included in this study with motion amplitude less than 11 mm. Our study supports the usage of IMPT to treat some lung cancer patients.

KW - intensity-modulated proton therapy

KW - interplay effects

KW - lung cancer

KW - volumetric-modulated arc therapy

UR - http://www.scopus.com/inward/record.url?scp=85055140101&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85055140101&partnerID=8YFLogxK

U2 - 10.1002/acm2.12459

DO - 10.1002/acm2.12459

M3 - Article

C2 - 30328674

AN - SCOPUS:85055140101

JO - Journal of Applied Clinical Medical Physics

JF - Journal of Applied Clinical Medical Physics

SN - 1526-9914

ER -